Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

New Drugs for 2022-2023

Annette Hayes, PharmD, BCPS, CDCES

Speaker:

Annette Hayes, PharmD, BCPS, CDCES

Clinical Assistant Professor, UIC College of Pharmacy Rockford

Learning Objectives:

At the completion of the activity, the participant will be able to:

  • List clinical indications and mechanisms of action for select new medications approved by the U.S. Food and Drug Administration in 2022 or with anticipated approval in late 2022 and 2023
  • Describe dosing, administration, safety, and efficacy of select new drugs with 2022/2023 FDA approval or anticipated approval
  • Identify patient specific factors to appropriately assess, monitor, and counsel patients receiving therapy
Target Audience: Pharmacists Fee: Free
Release Date: February 19, 2023 Expiration Date: January 16, 2025
Estimated time to complete: 1.0 hour CE: 1 contact hour (0.1 CEUs)

Go to activity

ACPE Heading link

ACPE Logo

How to Earn Credit:

Participants must complete the activity as described above in the Continuing Education Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on ‘Finish Attempt’, then click on ‘Submit All and Finish’ at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test, a confirmation message will appear at the top of the page underneath your grade. You will have a chance to review the correct answers and answer rationale.

Hardware/Software and Internet Requirements can be found at https://pharmacyce.uic.edu/moodle/.

Provider Contact Information:
For general information or questions,  email the Office of Continuing Education and Meeting Services at pharmce@uic.edu. Copyright © 2023– The Board of Trustees of the University of Illinois. All rights reserved. Reproduction in whole or in part without permission is prohibited. Privacy Policy